Clinical Trials
56 trialsNCT03765983 2026-05-27
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04578106 2026-01-06
ELPIS
Fundacio Clinic Barcelona
Phase 2 Terminated
NCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT05180006 2025-12-01
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT04789096 2025-06-06
TUGETHER
Breast Cancer Trials, Australia and New Zealand
Phase 2 Terminated
NCT04675827 2024-12-04
Decrescendo
Jules Bordet Institute
Phase 2 Terminated
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT01873833 2023-10-05
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
University of Southern California
Phase 2 Terminated
NCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT03931551 2023-02-22
OPHELIA
MedSIR
Phase 2 Terminated
NCT04510285 2023-02-01
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04168931 2023-01-17
GASTHER2
AC Camargo Cancer Center
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT02000596 2022-05-27
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
University of Maryland, Baltimore
Phase 2 Terminated
NCT00810017 2022-05-19
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT02213042 2021-10-13
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT02907918 2021-09-29
PALTAN
Washington University School of Medicine
Phase 2 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT01402401 2020-12-10
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Novartis
Phase 2 Terminated
NCT00138125 2020-10-19
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Translational Oncology Research International
Phase 2 Terminated
NCT04066790 2020-05-19
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Terminated
NCT02774681 2020-04-14
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
Northwestern University
Phase 2 Terminated
NCT02726399 2020-01-21
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT02598310 2019-08-28
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Osaka Medical College
Phase 2 Terminated
NCT00478140 2019-08-20
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00130507 2019-02-26
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT01185509 2019-01-23
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01912963 2018-12-05
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01690325 2018-08-13
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
West German Study Group
Phase 2 Terminated
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT00088985 2017-06-20
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00133796 2017-02-07
Neoadjuvant Herceptin in Patients With Breast Cancer
Baylor Breast Care Center
Phase 2 Terminated
NCT00427427 2016-08-01
Delayed Adjuvant HerceptinĀ® Treatment in Patients With HER-2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT00824733 2016-01-14
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00377780 2015-09-23
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Terminated
NCT01290718 2014-12-17
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
Hoffmann-La Roche
Phase 2 Terminated
NCT01928615 2014-09-29
LISAH
Hoffmann-La Roche
Phase 2 Terminated
NCT02013765 2014-09-25
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01363986 2014-08-11
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT02005484 2014-08-11
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
Hoffmann-La Roche
Phase 2 Terminated
NCT00079326 2014-06-02
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00118053 2013-11-20
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00724360 2013-10-07
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
Nantes University Hospital
Phase 2 Terminated
NCT00758134 2013-05-29
Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Istituto Clinico Humanitas
Phase 2 Terminated
NCT00004856 2013-05-03
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006015 2013-05-03
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated